The signal transduction events which govern major histocompatibility complex-unrestricted tumour cell destruction by nonspecific killer T lymphocytes induced with anti-CD3 antibody have not yet been determined. In this study we used Ž . Ž . pharmacologic inhibitors to investigate the role of protein tyrosine kinases PTK and protein kinase C PKC in this process. The PTK-inhibitors herbimycin A, genistein, and methyl 2,5-dihydroxycinnamate blocked anti-CD3-activated killer Ž . T AK-T lymphocyte-mediated killing of tumour target cells. The PKC-inhibitors staurosporine, calphostin C, and myristoylated PKC pseudosubstrate peptide, as well as PKC desensitization by phorbol 12-myristate 13-acetate pretreatment, also suppressed the cytolytic effector function of AK-T lymphocytes. Lack of tumoricidal activity was not due to reduced AK-T lymphocyte binding to tumour target cells but was associated with the abrogation of granule exocytosis, indicating that PTK and PKC are involved in the postbinding process which results in delivery of the 'lethal hit' by AK-T lymphocytes. q 1997 Elsevier Science B.V. All rights reserved.
Introduction
Activation of human and murine T lymphocytes Ž . with anti-CD3 monoclonal antibody mAb results in the generation of major histocompatibility complexAbbreviations: AK-T, anti-CD3-activated killer T; BLT, Na-CBZ-L-lysine thiobenzylester; CTL, cytotoxic T lymphocyte; DMSO, dimethyl sulfoxide; E:T, effector:target; mAb, monoclonal antibody; MDHC, methyl 2,5-dihydroxycinnamate; MTT, Ž . 3-4,5-dimethylthiazol-2-yl -2,5-diphenyltetrazolium bromide; myr-c PKC, myristoylated protein kinase C pseudosubstrate peptide; NK, natural killer; PKC, protein kinase C; PMA, phorbol 12-myristate 13-acetate; PTK, protein tyrosine kinase.
) Corresponding author. Fax: q1 902 4945125; E-mail: dwhoskin@is.dal.ca unrestricted killer T lymphocytes with nonspecific cytolytic activity against a range of tumour target w x cells 1-3 . Although little is known about how anti-Ž . CD3-activated killer T AK-T lymphocytes target tumour cells for cytolysis, recognition of tumour cells by AK-T lymphocytes apparently does not involve the T cell receptorrCD3 complex since these antigen-receptor complexes are rapidly modulated off the T cell-surface following exposure to anti-CD3 mAb w x 4,5 . Rather, the ability of AK-T lymphocytes to Ž . recognize and lyse natural killer NK cell-resistant, as well as NK-sensitive tumour target cells but not w x untransformed cells 3, 6 suggests that tumour recognition by AK-T lymphocytes may involve a receptor similar to the putative tumour recognition structure employed by other major histocompatibility Ž . complex-unrestricted cytotoxic T lymphocytes CTL w x and NK-derived lymphokine activated killer cells 7 .
T lymphocyte activation through the T cell receptorrCD3 complex, such as occurs following stimulation with specific antigen or anti-CD3 mAb, involves the activation of several distinct intracellular protein Ž . w x 2q tyrosine kinases PTK 8 , release of Ca from intracellular stores and the activation of protein ki-Ž .
2 q nase C PKC which is a phospholipidrCa -sensiw wx x tive protein serinerthreonine kinase reviewed in 9 . Sustained PKC activation in combination with increased intracellular free Ca 2q levels promotes the expression of several nuclear regulatory DNA-binding proteins and the induction of genes required for T w w x x cell proliferation and differentiation reviewed in 10 .
w x In a recent study Ting et al. 11 have shown that the pathway for AK-T lymphocyte induction which leads to the expression of cytolytic perforin and granzyme molecules is dependent on PKC activity but has a less stringent requirement for PTK activation. However, the requirement for PKC andror PTK activation to trigger cytolytic effector function by AK-T lymphocytes has yet to be determined.
In the present study we have employed pharmacologic inhibitors to determine whether PTK andror PKC activation are requisite steps in the process by which AK-T lymphocytes lyse tumour target cells. Herbimycin A, genistein and the erbstatin analogue Ž . methyl 2,5-dihydroxycinnamate MDHC were selected as PTK-inhibitors on the basis of the selective activity which these drugs exhibit against different w x PTK 8,12,13 . The highly specific PKC-inhibitors w x calphostin C 14 and myristoylated PKC pseudosub-Ž . w x strate peptide myr-c PKC 15 , as well as staurosporine, a commonly used but less selective PKCw x inhibitor 16 , and phorbol 12-myristate 13-acetate Ž . w x PMA desensitization 17 were used to inhibit PKC activity in AK-T lymphocytes. 
Materials and methods
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Cytolytic 51
Cr-release assay Ž 6 . Target cells 2-5 = 10 were incubated for 1 h at Ž . w 51 x 378C with 100 mCi 0.1 ml of Cr sodium chro-Ž . mate specific activity 250-500 mCirmg Cr; ICN , washed 3 times, and resuspended in complete RPMI 1640 medium at a concentration that would yield 5 = 10 3 target cellsrwell. AK-T lymphocytes, drugs Ž MDHC, genistein, calphostin C, myr-c PKC or stau-. rosporine or drug vehicle, and radiolabelled target cells were added sequentially to wells of a 96-well Ž 'V'-bottom microtiter plate Sarstedt, St. Laurent, . Que. in a final 0.2 ml volume of complete RPMI 1640 medium. In the case of herbimycin A and PMA treatments, AK-T lymphocytes were pretreated with these drugs for 18 h prior to the assay and were then washed extensively before use. Plates were incubated for 4 h at 378C in 95% humidified air and 5% CO , 2 centrifuged at 400 = g for 5 min, and 0.1 ml volumes of supernatant were collected from wells. 51 Cr released from lysed target cells was measured by auger and conversion electron counting with a Wallac 1410 scintillation counter. Percent lysis was calculated according to the formula
where E is the release from experimental samples, S is the spontaneous release, and M is the maximum release upon lysis with 10% sodium dodecyl sulfate. None of the drugs or drug vehicles in the concentrations used in this study had an effect on spontaneous 51 Cr release from target cells. Data are presented as the mean % lysis of triplicate or quadruplicate sam-Ž . ples "SD from a representative experiment. Each experiment was repeated at least 3 times.
Conjugate formation assay
P815 target cells were stained by incubation at Ž 378C for 10 min in the presence of neutral red dye 1 . mgrml in complete RPMI 1640 medium . The dye stained the cytoplasmic granules of P815 cells, allowing them to be readily distinguished from AK-T lymphocytes, without affecting cell viability as assessed by trypan blue dye exclusion. Stained P815 cells and AK-T lymphocytes were washed and resuspended at 5 = 10 6 cellsrml in complete RPMI 1640 Ž . medium. AK-T lymphocytes 0.1 ml and 0.1 ml of complete RPMI 1640 medium containing the desired concentration of genistein, staurosporine or calphostin C, an equivalent concentration of the drug vehicle, or Ž . anti-LFA-1 mAb 2.5 mgrml final concentration were added to 12 = 75 mm round-bottom polystyrene Ž . tubes Becton Dickinson, Lincoln Park, NJ , followed 10 min later by a 0.1 ml volume of target cells. In the case of herbimycin A, AK-T lymphocytes were pretreated with the drug for 18 h prior to the assay and then washed extensively before use. The tubes were centrifuged at 100 = g for 5 min and subsequently incubated for 30 min at 378C in 5% CO . The tubes 2 were then placed on ice and the conjugates were resuspended 5 times using a pipetman set at 200 ml. Unbound AK-T lymphocytes and AK-T lymphocytes conjugated to P815 cells were enumerated by microscopic examination in a hemocytometer. At least one hundred AK-T lymphocytes were counted. Each sample was counted blind in triplicate. The percentage of conjugated AK-T lymphocytes was calculated. Each experiment was performed at least twice.
BLT-esterase assay
To measure BLT-esterase activity released by AK-T lymphocytes during cytolytic assays, 0.05 ml of cell-free supernatant was transferred from each 'V'-bottom well to an empty well in a 96-well flat-( )bottom microtiter plate. Then 0.1 ml of 1 mM dithio-Ž . bis 2-nitrobenzoic acid and 0.05 ml of 2 mM BLT Ž . substrate both in phosphate-buffered saline were added to each well. The plate was incubated for 18 h at room temperature and the absorbance was read at Ž . 405 nM using a Titertek plate reader ICN . An absorbance of 0.01 was arbitrarily defined as 1 U of esterolytic activity. Data are represented as mean units of esterolytic activity in triplicate samples Ž . "SD from an experiment representative of 3 individual experiments.
Cell Õiability assays
51 w x w x Cr-release 20 and MTT 21 assays were used to evaluate the nonspecific toxicity of the PTK-and PKC-inhibitors used in this study. For 51 Cr-release viability assays, AK-T lymphocytes were loaded with 51 Ž Cr by incubation for 1 h at 378C with 100 mCi 0.1 . w 51 x Ž ml of Cr sodium chromate specific activity 250-. 500 mCirmg Cr; ICN , washed 3 times, and resuspended in complete RPMI 1640 medium at 10 6 Ž . cellsrml. Equal volumes 0.1 ml of AK-T cells and PTK-or PKC-inhibitors at the desired concentrations were added to quadruplicate wells of a 96-well 'V'-bottom microtiter plate and incubated for 4 h at 378C in 95% humidified air and 5% CO . After centri-2 fuging the plate at 400 = g for 5 min, 0.1 ml volumes of supernatant were collected from wells and 51 Cr-release was measured as previously described. Percent viability was calculated according to the formula
where D is the release from drug-treated AK-T cells, C is the release from untreated control AK-T cells, and M is the maximum release following lysis with 10% sodium dodecyl sulfate. In the case of MTT viability assays, 10 5 AK-T cells in a 0.2 ml volume of complete RPMI 1640 medium were incubated for 4 h at 378C in a 95% humidified atmosphere and 5% CO with various concentrations of the drugs in 2 quadruplicate wells of a 96-well microtiter plate. The AK-T cells were then washed twice with phosphate buffered saline and 200 ml of sterile MTT dye diluted 1:10 in complete RPMI 1640 medium was added to each well. AK-T cells were incubated at 378C for another 2 h. After pelleting the AK-T cells by centrifugation and removing the MTT solution, 100 ml of DMSO was added to each well and, following thorough mixing, spectrometric absorbance was measured at 492 nM using a Titertek plate reader. Data are expressed as % control MTT readings obtained with AK-T cell incubated in complete RPMI 1640 medium in the absence of PTK or PKC inhibitors.
Statistical analysis
Statistical comparisons of data were performed Ž using the Instat statistics program GraphPad Soft-. ware, San Diego, CA . One-way analysis of variance and the Bonferroni test was used for multiple comparisons while Student's t-test was used to compare differences between two different sample groups. P values less than 0.05 were considered to be statistically significant.
Results
PTK-inhibitors block AK-T lymphocyte-mediated lysis of tumour cells
To investigate the role of PTK in AK-T lymphocyte-mediated killing of tumour cells, we first evaluated the effect of herbimycin A pretreatment on the Ž b . ability of C57BLr6-derived H-2 haplotype AK-T Ž d lymphocytes to lyse P815 mastocytoma H-2 haplo-. type target cells. As shown in Table 1 , effector function was inhibited in a dose-dependent fashion by herbimycin A pretreatment with nearly complete inhibition occurring at 2 mM herbimycin A. A comparable dose-dependent inhibition of AK-T lymphocyte cytolytic activity was obtained in the presence of MDHC. Genistein at 100 and 50 mM concentrations was also effective in suppressing AK-T lymphocytemediated cytolysis. Although not shown, similar re-Ž a . sults were obtained when YAC-1 H-2 haplotype lymphoma cells were used instead of P815 cells as Ž . targets. The drug vehicle DMSO alone, at appropriate doses, had no significant effect on the cytolytic Ž . activity of AK-T lymphocytes data not shown . Effector cell viability, as determined by MTT and 51 Cr-release assays, was not substantially altered in the presence of the PTK-inhibitors with the exception of MDHC which, at the highest concentration used, appeared to cause a slight decrease in AK-T cell Ž . viability Table 2 . Ž . % Lysis after 4 h was measured at an effector:target E:T cell ratio of 50:1 as described in Section 2. NDs not determined. c One-way analysis of variance and Bonferroni test.
PKC inhibition interferes with AK-T lymphocyte cytolytic effector function
To determine whether PKC activity is required for AK-T lymphocytes to lyse tumour target cells, we examined the effect of several PKC-inhibitors on cytolytic activity against P815 mastocytoma cells. Data shown in Table 3 demonstrate that, in the presence of the PKC-inhibitors calphostin C and staurosporine, killing of P815 mastocytoma cells by AK-T lymphocytes was reduced in a dose-dependent fashion. In addition, we tested the effect of myr-c PKC, a cell-permeable synthetic peptide corresponding to the pseudosubstrate motif of PKC-a and -b subtypes w x 15 , on the tumoricidal activity of AK-T cells and observed a dose-dependent inhibition of P815 cytolysis. Furthermore, overnight exposure of AK-T lym- a AK-T lymphocytes were incubated for 4 h with complete RPMI 1640 medium alone or in the presence of increasing concentrations of PTK-inhibitors as described in Section 2. a AK-T lymphocytes were incubated for 4 h with complete RPMI 1640 medium alone or in the presence of increasing concentrations of PKC-inhibitors as described in Section 2.
phocytes to 1.6 mM PMA prior to their use in cytotoxicity assays resulted in a nearly complete loss of cytolytic activity, suggesting an important role for PKC in AK-T cell-mediated cytolysis since exposure of lymphocytes to this dose of PMA for extended periods of time is known to cause a selective loss of w x PKC activity 17 . We also investigated the effect of PKC-inhibitors on AK-T lymphocyte killing of YAC-Ž 1 lymphoma cells and obtained similar results data . not shown . Although not shown, the drug vehicles alone had no effect on the cytolytic activity of AK-T lymphocytes. The effect of PKC-inhibitors on effector cell viability was examined. As detailed in Table   4 , all drugs tested, with the exceptions of PMA and 0.5 mM calphostin C, had slight negative effects on AK-T lymphocyte viability when viability was determined by MTT assay. On the other, little or no cytotoxicity due to the PKC-inhibitors was observed when 51 Cr-release was used to assess AK-T cell viability. In any case, the observed effects on AK-T lymphocyte viability were of insufficient magnitude to account for the strong inhibition of cytolytic effector function by the various PKC-inhibitors when used at the same or lower concentrations.
Effector-to-target cell conjugation is not affected by PTK or PKC inhibition
We next performed conjugation assays to determine whether PTK andror PKC activation is involved in AK-T lymphocyte binding to tumour cells. Ž As shown in Table 5 , neither PTK-herbimycin A, . Ž genistein nor PKC-inhibitors calphostin C, stau-. rosporine , at concentations that were strongly in-Ž hibitory to AK-T lymphocyte cytolytic activity see . Tables 1 and 3 , were able to significantly affect AK-T lymphocyte conjugation to P815 target cells. In contrast, treatment with anti-LFA-1 mAb, which was used as a positive control in these experiments, greatly Table 5 Effect of PTK-and PKC-inhibitors on AK-T lymphocyte binding to P815 target cells a b c
Expt. Treatments % Conjugation" SD Significance These data indicate that PTK and PKC inhibition disrupts processes which occur during the postbinding stage of AK-T lymphocyte-mediated cytolysis.
PTK and PKC inhibition abolishes BLT esterase release by AK-T lymphocytes
Granule exocytosis, which is a major mechanism by which killer lymphocytes deliver the 'lethal hit' to target cells, is an important postbinding event in w x AK-T lymphocyte-mediated lysis of tumour cells 19 . We therefore tested the effect of PTK and PKC inhibition on granule exocytosis, as determined by the release of BLT esterase activity which co-localizes with cytolytic effector molecules such as perforin within the cytoplasmic granules of AK-T lymw x phocyte 11 . AK-T lymphocytes pretreated with herbimycin A to inactivate PTK, or AK-T lymphocytes Fig. 1 . Effect of PTK and PKC inhibition on granule exocytosis by AK-T lymphocytes. A. AK-T lymphocytes pretreated with the Ž . drug vehicle or the PTK-inhibitor herbimycin A 1 mM for 18 h prior to the assay were washed and added to P815 target cells at an E:T ratio of 50:1. B. AK-T lymphocytes were combined with P815 target cells at an E:T ratio of 50:1 in the presence or Ž . absence of the PKC-inhibitor calphostin C 0.5 mM . In both cases, after 4 h the release of BLT esterase activity was measured as described in Section 2. Statistical significance was determined Ž ) . Ž ) ) . by Student's t-test; denotes P s 0.0004, denotes P s 0.0077. treated with calphostin C to block PKC activity were incubated for 4 h with P815 target cells and the subsequent release of BLT esterase activity was measured in a colorimetric BLT esterase assay. We observed that release of BLT esterase activity by AK-T lymphocytes was reduced by almost 90% when PTK Ž . Ž . Fig. 1A or PKC Fig. 1B activity was inhibited, indicating that PTK and PKC are involved in the release of cytoplasmic granule contents by AK-T lymphocytes.
Discussion
The biochemical events involved in recognition and lysis of virally-infected or transformed target cells by antigen-specific CTL have been well characterized. Triggering of antigen-specific CTL through the T cell receptorrCD3 complex leads to a cascade of biochemical events involving PTK and PKC actiw x vation, and culminating in target cell lysis 22,23 . However, the signal transduction pathways involved in the T cell receptor-independent recognition and lysis of tumour target cells by nonspecific killer T lymphocytes induced with anti-CD3 mAb have not yet been defined. The present study provides evidence that protein tyrosine phosphorylation and PKC activation are important steps in AK-T lymphocytemediated killing of tumour target cells, because either PTK or PKC inhibition by pharmacologic inhibitors caused a marked reduction in the tumoricidal activity of AK-T lymphocytes. For the most part, neither the PTK-nor the PKC-inhibitors employed in our experiments had any substantial effect on the viability of AK-T lymphocytes over the course of 4-hr cytolytic 51 Cr-release assays. We used two different assays to evaluate AK-T cell viability following exposure to PTK-or PKC-inhibitors: the 51 Cr-release permeability assay, which measures alterations in cellular w x membrane integrity 20 ; and the MTT assay which measures changes in the function of mitochondrial w x dehydrogenases 21 . Both assays are considered to be acceptable methods of determining cell viability in w x mammalian cell culture systems 24 . Furthermore, AK-T lymphocytes conjugated normally to tumour target cells and released dramatically less BLT esterase in the presence of PTK-or PKC-inhibitors. Nonspecific cytotoxicity caused by the PTK-and ( )PKC-inhibitors would be expected to alter effector cell adhesion to target cells and, if anything, increase BLT esterase secretion as cell membrane permeability was compromised. In agreement with previous reports that PTK-and PKC-inhibitors have minimal w x effects on lymphocyte viability 11,25 , we conclude that diminished killing of tumour cells in the presence of PTK-and PKC-inhibitors was not due to nonspecific toxic effects of the drugs on the AK-T cells.
The pharmacologic approach which we have taken to investigate the requirement for PTK and PKC activity in AK-T lymphocyte effector function is well established. Herbimycin A, genistein, and MDHC have been widely used to inhibit the activity of PTK involved in a number of receptor-associated T cell w x signaling pathways 11, [26] [27] [28] . Previous studies have demonstrated that PKC signaling in T lymphocytes is intact in the presence of the PTK inhibitors used in w x w x our study 26,29-31 . For example, Osorio et al. 30 observed that herbimycin A does not affect the upregulation of CD25 expression induced through the w x activation of PKC by phorbol ester 32 . Similarly, genistein has no effect on PMA-induced expression w x of CD69 by T cells 31 , which is a PKC-dependent w x event 33 . Herbimycin A degrades src-family PTK without affecting the serinerthreonine kinases, PKC w x and c-raf 26 . On the other hand, genistein and w x MDHC are competitive PTK-inhibitors 12,13 and must therefore be present during the cytotoxicity assay to mediate PTK inhibition, raising the possibility that these drugs might also somehow affect the tumour target cells. However, since herbimycin A was not present during the cytotoxicity assay, any possible untoward effect of PTK inhibition on tumour cell susceptibility to lysis can be discounted. Our data therefore indicate that AK-T lymphocyte-associated protein tyrosine phosphorylation is critical for tumoricidal activity.
A number of recent studies have employed calphostin C and staurosporine to inhibit PKC-dependent signaling pathways in T lymphocytes w x 11,28,34,35 . PTK signaling in T cells is intact in the presence of either staurosporine or calphostin C because neither drug affects PTK-dependent Ca 2q mow x bilization responses 34 or IgD receptor expression w x 28 . Staurosporine is a commonly used PKC-inhibitor which acts by targeting the proteolytically generw x ated catalytic domain of PKC 16 . However, staurosporine also inhibits protein kinase A and protein kinase B because of the striking degree of homology which exists between these protein kinases and PKC w w x x reviewed in 36 . It was therefore possible that the observed inhibitory effect of staurosporine on AK-T lymphocyte function could be attributed at least in part to the nonspecific inhibition of other protein kinases. In order to exclude this possibility, we also used calphostin C and myr-c PKC, both of which are w x highly selective inhibitors of PKC 14,15 . Calphostin C targets the regulatory domain of PKC, which is w x distinct from those of other protein kinases 37 . Myr-c PKC interacts with the substrate binding site in the catalytic domain of PKC, thereby keeping the w x enzyme in its inactive state 15 . As with staurosporine, an inhibitory effect on the cytolytic effector function of AK-T lymphocytes was observed in the presence of both calphostin C and myr-c PKC.
Since it is well established that PMA-sensitive PKC isoforms are downregulated in T lymphocytes by Ž . w x overnight treatment 16 h with PMA 17,38 , we also used long-term exposure to PMA to cause a selective loss of PKC activity in AK-T lymphocytes prior to their use in cytotoxicity assays. The subsequent reduction in the tumoricidal activity of AK-T lymphocytes which we observed suggests that reduced cytolysis in the presence of PKC-inhibitors is not due to any untoward effect of the PKC-inhibitors on tumour cell susceptibility to lysis. Taken together, our data indicate that PKC activity is required for AK-T lymphocytes to lyse tumour target cells.
We also investigated the effect of PTK and PKC inhibition on binding and postbinding stages in the lytic process. A visual binding assay was employed to determine whether the suppressive effect of PTK andror PKC inhibition on AK-T lymphocyte effector function could be attributed to reduced conjugate formation between AK-T lymphocytes and P815 tumour cells. Antigen-specific CTL adhesion to alloantigen-bearing target cells has been reported to w x depend on protein tyrosine phosphorylation 39 and may, to a lesser extent, also involve PKC activation w x 23,40 . However, inhibition of PTK or PKC activity by treatment with pharmacologic inhibitors, at doses which prevented tumour cell lysis in our cytotoxicity assays, had no discernable effect on the ability of AK-T lymphocytes to conjugate to P815 target cells. We conclude that PTK and PKC activation is required during the postbinding stage of AK-T lymphocyte-mediated lysis. Interestingly, anti-LFA-1 mAb Ž employed as a positive control in our binding as-. says caused a 52-77% inhibition in conjugate formation, indicating that the interaction of LFA-1 with its ligands plays an important role in AK-T lymphocyte binding to P815 mastocytoma cells. In addition, Ž . activation of PTK s associated with LFA-1 has recently been implicated in triggering NK cytotoxicity w x 41 , suggesting a possible role for LFA-1 in triggering AK-T lymphocytes to kill tumour cells.
We observed that inhibition of either protein tyrosine phosphorylation or PKC activation resulted in the virtual abrogation of tumour cell-induced granule exocytosis by AK-T lymphocytes. Other investigators who have examined the role of PTK and PKC activation in antigen-specific CTL, as well as NK cell effector function have reported similar findings w x 22,23,42,43 , suggesting that the biochemical events involved in the postbinding stage of nonspecific AK-T lymphocyte-mediated lysis of tumour cells may be common to the function of other cytolytic effector cells. Furthermore, our data suggest that PTK andror PKC activation may be obligatory steps in the postbinding signal transduction cascade which activates the cytolytic machinery of AK-T lymphocytes. PTK andror PKC may also be directly involved in the release of granule contents by AK-T cells, as has been proposed for PTK in granule secretion by neuw x w x trophils 44 and antigen-specific CTL 22 . Unfortunately, the pharmacologic approach that we have employed does not allow us to differentiate between PTK andror PKC regulation of early or distal events in the postbinding stage of AK-T lymphocyte-mediated lysis. Nevertheless, since AK-T lymphocytes depend primarily on granule-associated cytolytic w x molecules to mediate P815 killing 19 , our findings indicate the protein tyrosine phosphorylation and PKC activation play important roles in regulating the process by which AK-T lymphocytes deliver the 'lethal hit' to tumour target cells.
